Drug Profile
Travoprost/timolol
Alternative Names: 0.004% travoprost/0.5% timolol; DuoTrav; DuoTrav APS; DuoTrav® PQ; DuoTrav™ BAK; Extravan; Timolol/travoprost; Travoprost + Timolol Fixed Combination; TTFCLatest Information Update: 15 Apr 2019
Price :
$50
*
At a glance
- Originator Alcon
- Developer Alcon; Novartis
- Class Antiglaucomas; Antihypertensives; Propanolamines; Prostaglandins; Thiadiazoles
- Mechanism of Action Beta-adrenergic receptor antagonists; Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Glaucoma
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
- 27 Jan 2017 Novartis has patent protection for travoprost/timolol in Europe and Japan (Novartis 20-F filed in 2017)
- 13 Apr 2015 No recent reports on development identified - Preregistration for Glaucoma in USA (Ophthalmic)